Washington, DC 20006-5349
HELPLINE
Today, the Meso Foundation wrote a letter to the acting administrator of the EPA urging the agency to account for legacy asbestos when evaluating asbestos risk and the magnitude of the asbestos problem. This letter came as a response to the EPA’s decision to exclude legacy uses of asbestos in its problem formulation. This issue is separate from the recently publicized ‘significant new use rule.’ You can read more here.
EPA_Legacy_Comment_MesoFoundation
Mesothelioma treatments are diverse. When a patient sees their oncologist, they may hear differing treatment options. These sessions focus on the different tools for treatment
Mesothelioma is rare cancer that can be extremely confusing for newly diagnosed patients and their families. This session focuses on the commonly used terms and
Many mesothelioma patients beat their odds and go on to live rich, fulfilling lives. This panel has three long term patients who discuss the issues
Get the latest information about mesothelioma, clinical trials, patient stories, community events, and much more!
